Arbutus Biopharma Corp Deferred Income Tax Expense (Benefit)
Arbutus Biopharma Corp (ABUS) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2021-03-04
- Arbutus Biopharma Corp deferred income tax expense (benefit) for the quarter ending 2019-12-31 was $0.00.
- Arbutus Biopharma Corp deferred income tax expense (benefit) for the quarter ending 2019-09-30 was -$12.66M.
- Arbutus Biopharma Corp deferred income tax expense (benefit) for the quarter ending 2018-12-31 was $0.00.
- Arbutus Biopharma Corp deferred income tax expense (benefit) for the quarter ending 2018-09-30 was -$4.28M.
- Arbutus Biopharma Corp deferred income tax expense (benefit) for fiscal 2020 was $0.00.
- Arbutus Biopharma Corp deferred income tax expense (benefit) for fiscal 2019 was -$12.66M.
- Arbutus Biopharma Corp deferred income tax expense (benefit) for fiscal 2018 was -$4.28M.
- Arbutus Biopharma Corp deferred income tax expense (benefit) for fiscal 2017 was -$24.32M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-04 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$12.66M derived: sum of 2 quarters · filed 2021-03-04 | -$12.66M 10-K · filed 2021-03-04 | |
| 2019-09-30 | -$12.66M 10-Q · filed 2019-11-06 | -$12.66M 10-Q · filed 2019-11-06 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | -$4.28M derived: sum of 2 quarters · filed 2020-03-05 | -$4.28M 10-K · filed 2020-03-05 | |
| 2018-09-30 | -$4.28M 10-Q · filed 2019-11-06 | -$4.28M 10-Q · filed 2019-11-06 | ||
| 2017-12-31 | -$24.32M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$24.32M derived: sum of 2 quarters · filed 2019-03-07 | -$24.32M derived: sum of 3 quarters · filed 2019-03-07 | -$24.32M 10-K · filed 2019-03-07 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-03 | $0.00 10-Q · filed 2017-08-03 | ||
| 2016-12-31 | -$40.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$40.20M derived: sum of 2 quarters · filed 2018-03-16 | -$105.06M derived: sum of 3 quarters · filed 2018-03-16 | -$105.06M 10-K · filed 2018-03-16 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-02 | -$64.86M derived: sum of 2 quarters · filed 2017-11-02 | -$64.86M 10-Q · filed 2017-11-02 | |
| 2016-06-30 | -$64.86M 10-Q · filed 2017-08-03 | -$64.86M 10-Q · filed 2017-08-03 | ||
| 2015-12-31 | -$989.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$16.18M derived: sum of 2 quarters · filed 2018-03-16 | -$16.18M derived: sum of 3 quarters · filed 2018-03-16 | -$16.18M 10-K · filed 2018-03-16 |
| 2015-09-30 | -$15.20M 10-Q · filed 2016-11-03 | -$15.20M derived: sum of 2 quarters · filed 2016-11-03 | -$15.20M 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $0.00 10-Q · filed 2016-08-04 | $0.00 10-Q · filed 2016-08-04 | ||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-22 | $0.00 derived: sum of 2 quarters · filed 2017-03-22 | $0.00 10-K · filed 2017-03-22 | |
| 2014-09-30 | $0.00 10-Q · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 | ||
| 2013-12-31 | $0.00 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |